TD Cowen Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35
TD Cowen Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $18
BMO Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $24
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Announces Target Price $18
Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $28
ACADIA Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $28 Price Target
RBC Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Analyst Ratings
Morgan Stanley Assumes ACADIA Pharmaceuticals at Equal-Weight, Maintains Price Target of $20
Morgan Stanley Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $20
Morgan Stanley Initiates ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Announces Target Price $20
J.P. Morgan Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $25
Guggenheim Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Maintains Target Price $20
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $20 to $37
Analysts' Opinions Are Mixed on These Healthcare Stocks: Universal Health (UHS), MiMedx Group (MDXG) and ACADIA Pharmaceuticals (ACAD)
ACADIA Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $20 to $37
ACADIA Pharmaceuticals Analyst Ratings